FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
|Videos|October 6, 2020
FDA Advancements in HER2+ Breast Cancer
Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.
Advertisement
Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.
Advertisement
Related to this article
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
Oncology nursing teams must navigate the clinical logistics and patient education for the newly approved, ctDNA-guided agent camizestrant.
Oncology navigator Emily Beard shares insights on advocacy, the Young Survival Coalition, and dancing to sustain her career.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC
2
Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma
3
Prostate Cancer Care: ADT Management and APP Guidance
4
Why Using AI to Interpret Mammogram Results Can Cause Unnecessary Panic
5